Nuclear receptor peroxisome proliferator-activated receptor-γ is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen

Journal of Neurochemistry

Volumn 92, Issue 4, 2005, Pages 895-903

  Bernardo, Antonietta ^a   Ajmone Cat, Maria Antonietta ^a   Gasparini, Laura ^b   Ongini, Ennio ^b   Minghetti, Luisa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Nicox Research Institute   (Italy)

Author keywords

15 deoxy 12,14 prostaglandin J2; Brain macrophages; Ciglitazone; HCT1026; Neuroinflammation; Peroxisome proliferator activated receptor

Indexed keywords

ANTIINFLAMMATORY AGENT; CELL NUCLEUS RECEPTOR; CIGLITAZONE; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROSTAGLANDIN J2;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL KINETICS; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; FATTY ACID ANALYSIS; HORMONAL REGULATION; INFLAMMATION; MICROGLIA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CEREBRAL CORTEX; FLURBIPROFEN; MICROGLIA; PPAR GAMMA; RATS; RATS, WISTAR;

EID: 13644260454     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02932.x     Document Type: Article

References (51)

1. Agresti C., D'Urso D. and Levi G. (1996) Reversible inhibitory effects of interferon-γ and tumor necrosis factor-α on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur. J. Neurosci. 8, 1106-1116.
2. 2, interleukin-1β and nitric oxide synthesis by activated microglia. J. Neurosci. Res. 66, 715-722.
3. 2 synthesis in microglia. J. Neurochem. 87, 1193-1203.
4. Aldini G., Carini M., Oriolo M., Maffei Facino R. and Wenk G. L. (2002) Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: a LC-MS study. Life Sci. 71, 1487-1500.
5. Bannwarth B., Lapicque F., Pehourcq F., Gillet P., Schaeverbeke T., Laborde C., Dehais J., Gaucher A. and Netter P. (1995) Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br. J. Clin. Pharmacol. 40, 266-269.
6. 2 in the regulation of microglial functions. Eur. J. Neurosci. 12, 2215-2223.
7. Bernardo A., Ajmone-Cat M. A., Levi G. and Minghetti L. (2003) 15-deoxy-Δ12,14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms. J. Neurochem. 87, 742-751.
8. Bertrand V., Guimbaud R., Sogni P., Lamrani A., Mauprivez C., Giroud J. P., Couturier D., Chauvelot-Moachon L. and Chaussade S. (1998) Role of tumor necrosis factor-α and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity. Eur. J. Pharmacol. 356, 245-253.
9. Bishop-Bailey D. and Warner T. D. (2003) PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-γ antagonist. FASEB J. 17, 1925-1927.
10. Borchelt D. R., Thinakaran G., Eckman C. B. et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/ 1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
11. Burgaud J. L., Ongini E. and Del Soldato P. (2002) Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. N. Y. Acad. Sci. 962, 360-371.
12. Castrillo A., Diaz-Guerra M. J., Hortelano S., Martin-Sanz P. and Bosca L. (2000) Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta (12, 14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20, 1692-1698.
13. De Simone R., Ajmone-Cat M. A., Tirassa P. and Minghetti L. (2003) Apoptotic PC12 cells exposing phosphatidylserine promote the production of anti-inflammatory and neuroprotective molecules by microglial cells. J. Neuropathol. Exp. Neurol. 62, 208-216.
14. Diab A., Deng C., Smith J. D., Hussain R. Z., Phanavanh B., Lovett-Racke A. E., Drew P. D. and Racke M. K. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis..J. Immunol. 168, 2508-2515.
15. Eriksen J. L., Sagi S. A., Smith T. E. et al. (2003) NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112, 440-449.
16. Feinstein D. L., Galea E., Gavrilyuk V., Brosnan C. F., Whitacre C. C., Dumitrescu-Ozimek L., Landreth G. E., Pershadsingh H. A., Weinberg G. and Heneka M. T. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694-602.
17. Fiorucci S., Antonelli E., Santucci L., Morelli O., Miglietti M., Federici B., Mannucci R., Del Soldato P. and Morelli A. (1999) Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenlerology 116, 1089-1106.
18. Fiorucci S., Santucci L., Cirino G., Mencarelli A., Familiari L., Soldato P. D. and Morelli A. (2000) IL-1β converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J. Immunol. 165, 5245-5254.
19. Fiorucci S., Santucci L., Gresele P., Faccino R. M., Del Soldato P. and Morelli A. (2003) Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124, 600-607.
20. Furlan R., Kume A., Bergami A., Brambilla E., Maucci R., Gasparini L., Butti E., Comi G., Ongini E. and Martino G. (2004) A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J.Neuroimmunol. 150, 10-19.
21. Gasparini L., Rusconi L., Xu H., Del Soldato P. and Ongini E. (2004) Modulation of β-amyloid metabolism by non-steroidal antiinflammatory drugs in neuronal cell cultures. J. Neurochem. 88, 337-348.
22. 2 synthesis in brain macrophages by inhibiting the enzymatic activity of cyclooxygenase but not phospholipases and prostaglandin E synthase. J. Neurosci. Res. 71, 844-852.
23. Guastadisegni C., Minghetti L., Nicolini A., Polazzi E., Ade P., Balduzzi M. and Levi G. (1997) Prostaglandin E2 synthesis is differentially affected by reactive nitrogen intermediates in cultured rat microglia and RAW 264.7 cells. FEBS Lett. 413, 314-318.
24. Hauss-Wegrzyniak B., Willard L. B., Del Soldato P., Pepeu G. and Wenk G. L. (1999) Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res. 815, 36-43.
25. Johal K. and Hanson J. P. (2000) Opposite effects of flurbiprofen and the nitroxybutylester of flurbiprofen on apoptosis in cultured guinea pig gastric mucous cells. Br. J. Pharmacol. 130, 811-818.
26. Keeble J. E. and Moore P. K. (2002) Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 137, 295-310.
27. Kielian T. and Drew P. D. (2003) Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation. J. Neurosci. Res. 71, 315-325.
28. Kondo M., Shibata T., Kumagai T., Osawa T., Shibata N., Kobayashi M., Sasaki S., Iwata M., Noguchi N. and Uchida K. (2002) 15-Deoxy-Delta (12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc. Natl Acad. Sci. USA 99, 7367-7372.
29. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M. and Kliewer S. A. (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
30. Levi G., Patrizio M., Bernardo A., Petrucci T. C. and Agresti C. (1993) Human immunodeficiency virus coat protein gp120 inhibits the β-adrenergic regulation of astroglial and microglial functions. Proc. Natl Acad. Sci. U.S.A. 90, 1541-1545.
31. Minghetti L. and Levi G. (1995) Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J. Neurochem. 65, 2690-2698.
32. Minghetti L., Polazzi E., Nicolini A., Creminon C. and Levi G. (1996) IFN-γ and nitric oxide down-regulate LPS-induced production in cultured rat microglial cells. J. Neurochem. 66, 1963-1970.
33. Morihara T., Chu T., Ubeda O., Beech W. and Cole G. M. (2002) Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem. 83, 1009-1012.
34. Mosmann T. R. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Meth. 65, 55-63.
35. Nosjean O. and Boutin J. A. (2002) Natural ligands of PPAR gamma: are prostaglandin J(2) derivatives really playing the part? Cell Signal. 14, 573-583.
36. Pang L., Nie M., Corbett L. and Knox A. J. (2003) Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J. Immunol. 170, 1043-1051.
37. Perez-Ortiz J. M., Tranque P., Vaquero C. F., Domingo B., Molina F., Calvo S., Jordan J., Cena V. and Llopis J. (2004) Glitazones differentially regulate primary astrocyte and glioma cell survival: involvement of ROS and PPARγ. J. Biol. Chem. 279, 8976-8985.
38. Petrova T. V., Akama K. T. and Van Eldik L. J. (1999) Cyclopentenone prostaglandins suppress activation of microglia: downregulation of inducible nitric-oxide synthase by 15-deoxy-Del-ta12,14-prostaglandin J2. Proc. Natl. Acad. Sci. USA 96, 4668-4673.
39. Prosperi C., Scali C., Pepeu G. and Casamenti F. (2001) NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn. J. Pharmacol. 86, 230-235.
40. Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
41. Rosi S., McGann K., Hauss-Wegrzyniak B. and Wenk G. L. (2003) The influence of brain inflammation upon neuronal adenosine A2B receptors. J. Neurochem. 86, 220-227.
42. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M. and Santoro M. G. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403, 103-108.
43. Sagi S. A., Weggen S., Eriksen J., Golde T. E. and Koo E. H. (2003) The non-COX targets of NSAIDs, lipoxygenases, PPARs, IKK, and NFkB, do not reduce Aβ42 production. J. Biol. Chem. 278, 31 825-31 830.
44. Santini G., Sciulli M. G., Panara M. R., Pàdovano R., Di Giamberardino M., Rotondo M. T., Del Soldato P. and Patrignani P. (1996) Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases. Eur. J. Pharmacol. 316, 65-72.
45. Sastre M., Dewachter I., Landreth G. E., Willson T. M., Klockgether T., van Leuven F. and Heneka M. T. (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23, 9796-9804.
46. Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D. L. and Heneka M. T. (2004) Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients. J. Leukoc. Biol. 75, 478-485.
47. Shibuya A., Wada K., Nakajima A., Saeki M., Katayama K., Mayumi T., Kadowaki T., Niwa H. and Kamisaki Y. (2002) Nitration of PPAR-γ inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett. 525, 43-47.
48. Tegeder I., Pfeilschifter J. and Geisslinger G. (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15, 2057-2072.
49. Van Groen T. and Kadish I. (2004) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res. Rev., in press.
50. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216.
51. Willson T. M., Lambert M. H. and Kliewer S. A. (2001) Peroxisome proliferator-activated receptor γ and metabolic disease. Ann. Rev. Biochem. 70, 341-367.